LAVAL, CANADA, and CAMBRIDGE, ENGLAND – June 30, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, today provided a guidance update on the timing of certain expected key milestones for 2020. “While we announced in May the withdrawal of all previously issued guidance on expected key milestones for our business given the uncertainty created by the global COVID-19 pandemic and the priority on the health and safety of our employees during this pandemic, we are continuing to execute and move our business forward, and remain committed to providing further updates on certain key expected milestones, as appropriate.” stated Kenneth Galbraith, Chief Executive Officer of Liminal BioSciences. “We now expect the following timing for two important priorities of the Company for 2020: - The re-submission of our biologics licensing application (BLA) with the US Food and Drug Administration (FDA) for Ryplazim® (plasminogen) for the treatment of congenital plasminogen deficiency is anticipated to be filed in the third quarter of 2020; and
- Our multiple ascending dose (MAD) Phase 1 clinical study of fezagepras is expected to be initiated in the second half of 2020.”
|